원발성 면역결핍증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.8%의 성장률로 95억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 피하 요법의 채택 확대, 의료 접근성 개선, 연구 개발 활성화, 효율적인 치료에 대한 수요 증가, 면역글로불린 대체 요법에 대한 수요 증가에 기인합니다. 예측 기간 동안 주요 동향으로는 생명공학 기술의 발전, 혁신적인 유전자 치료 및 생물학적 제제, 유전자 검사 및 맞춤 의료의 발전, 유전자 치료 및 유전자 검사의 지속적인 발전 등을 들 수 있습니다.
자가면역질환의 유병률 증가는 원발성 면역결핍증 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 면역체계가 신체의 건강한 세포와 조직을 외부의 적으로 잘못 인식하여 공격할 때 발생합니다. 이러한 잘못된 면역 반응은 다양한 장기와 시스템에 염증과 손상을 일으킵니다. 자가면역질환의 증가는 환경적 요인, 유전적 소인, 생활습관의 변화 등이 복합적으로 얽혀 있기 때문으로 여겨지고 있습니다. 이들 질환은 면역 조절을 방해하고 면역 세포를 공격하여 면역 반응을 약화시키거나 손상시켜 원발성 면역결핍증을 유발합니다. 예를 들어, 2024년 11월 독일의 양방향 온라인 플랫폼인 Versorgungsatlas.de의 데이터에 따르면, 2022년 7,324만 1,305명의 피보험자 중 630만 4,340명이 적어도 한 가지 이상의 자가면역질환을 진단받았으며, 유병률은 8.61%였습니다. 61%였습니다. 이러한 자가면역질환의 유병률 증가는 원발성 면역결핍증 시장 확대의 주요 촉진요인으로 작용하고 있습니다.
원발성 면역결핍증 시장의 주요 기업들은 면역기능을 개선하여 환자의 예후를 개선하기 위해 면역글로불린 정맥주사 요법(IVIG 요법)과 같은 첨단 치료법 개발에 주력하고 있습니다. 투여하는 것입니다. 예를 들어, 2024년 6월 스페인에 본사를 둔 헬스케어 기업 그리폴스(Grifols)는 정맥 내 면역글로불린(IVIG) 요법인 이무고(Yimmugo)의 FDA 승인을 획득했습니다. 이 새로운 무설탕의 즉시 사용 가능한 IgG 용액은 인간 혈장 유래이며 정맥 투여를 목적으로 합니다. 미국에서 일차 항체결핍증 환자의 대체요법으로 승인된 Yimmugo는 면역결핍 환자를 위한 항체 대체요법을 제공하고 보다 안전하고 효과적인 감염 방어 솔루션을 제공함으로써 글리볼룸의 혈장 기반 치료 포트폴리오를 강화할 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 원발성 면역결핍증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 원발성 면역결핍증 시장 : 성장률 분석
- 세계의 원발성 면역결핍증 시장 실적 : 규모와 성장, 2019-2024
- 세계의 원발성 면역결핍증 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 원발성 면역결핍증 전체 시장(TAM)
제6장 시장 세분화
- 세계의 원발성 면역결핍증 시장 : 질환별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 항체 결핍증
- 세포성 면역결핍증
- 선천성 면역질환
- 기타 질병
- 세계의 원발성 면역결핍증 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 면역글로불린 보충 요법
- 항생제 요법
- 줄기세포와 골수 이식
- 유전자 치료
- 기타 치료법
- 세계의 원발성 면역결핍증 시장 진단 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 유전자 검사
- 혈액 검사
- 유세포 분석
- 기타 진단 종류
- 세계의 원발성 면역결핍증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 전문 클리닉
- 재택 케어 설정
- 조사기관
- 세계의 원발성 면역결핍증 시장 항체 결핍증 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 분류 불가능 형태 면역결핍증(CVID)
- IgA 결핍증
- IgG 서브 클래스 결핍증
- 특이적 항체 결핍증
- 세계의 원발성 면역결핍증 시장 세포성 면역결핍증 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 중증복합면역결핍증(SCID)
- T세포 결핍증
- 디조지 증후군
- 위스코트-알드리치 증후군
- 세계의 원발성 면역결핍증 시장, 자연 면역질환 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 만성 육아종성 질환(CGD)
- 보체 결핍증
- 톨유사수용체 결핍증
- 체디악-히가시 증후군
- 세계의 원발성 면역결핍증 시장 기타 질환 하위 세분화(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 고IgM 증후군
- 고IgE 증후군
- 모세혈관확장성 운동실조증
- 증후군성 특징을 수반하는 복합 면역결핍증
제7장 지역별·국가별 분석
- 세계의 원발성 면역결핍증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 원발성 면역결핍증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 원발성 면역결핍증 시장 : 경쟁 구도
- 원발성 면역결핍증 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- Takeda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- CSL Behring Overview, Products and Services, Strategy and Financial Analysis
- Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Grifols SA
- Octapharma
- Kedrion Biopharma
- Miltenyi Biotec
- LFB Group
- Clinigen Limited
- ADMA Biologics Inc.
- Bio Products Laboratory Ltd
- BD Biosciences
- Cellectis SA
- Florencia Healthcare
- X4 Pharmaceuticals Inc.
- Amber Lifesciences
- bluebird bio Inc.
- Chengdu Rongsheng Pharmaceutical Co Ltd
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 원발성 면역결핍증 시장 2029 : 새로운 기회를 제공하는 국가
- 원발성 면역결핍증 시장 2029 : 새로운 기회를 제공하는 부문
- 원발성 면역결핍증 시장 2029 : 성장 전략
제36장 부록
ksm
Primary immunodeficiency disorders (PIDs) are inherited conditions that impair the immune system, making individuals more susceptible to infections, autoimmune diseases, and certain cancers. Early diagnosis and identification of PIDs are critical for effective treatment, infection prevention, and improving patient health through therapies such as immunoglobulin replacement or bone marrow transplants.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of primary immunodeficiency disorders include antibody deficiencies, cellular immunodeficiencies, innate immune disorders, and others. Antibody deficiencies occur when the immune system is unable to produce sufficient antibodies, which are responsible for detecting and neutralizing harmful pathogens. Treatments available include immunoglobulin replacement therapy, antibiotic treatment, stem cell or bone marrow transplants, gene therapy, and other methods. Diagnostic approaches involve genetic testing, blood tests, flow cytometry, and other techniques, which are typically applied in hospitals, specialty clinics, home care settings, and research institutions.
The primary immunodeficiency disorders market research report is one of a series of new reports from The Business Research Company that provides primary immunodeficiency disorders market statistics, including the primary immunodeficiency disorders industry's global market size, regional shares, competitors with a primary immunodeficiency disorders market share, detailed primary immunodeficiency disorders market segments, market trends and opportunities, and any further data you may need to thrive in the primary immunodeficiency disorders industry. This primary immunodeficiency disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary immunodeficiency disorders market size has grown strongly in recent years. It will grow from$6.84 billion in 2024 to $7.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the rising incidence of primary immunodeficiency disorders, increased awareness among healthcare professionals, growing demand for effective treatments, higher research funding, and an increased focus on pediatric care.
The primary immunodeficiency disorders market size is expected to see strong growth in the next few years. It will grow to$9.51 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the growing adoption of subcutaneous therapies, improved healthcare access, robust research and development, a higher demand for efficient treatments, and an increasing need for immunoglobulin replacement therapy. Major trends in the forecast period include advancements in biotechnology, innovative gene therapies and biologics, progress in genetic testing and personalized medicine, and ongoing advancements in gene therapy and genetic tests.
The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the primary immunodeficiency disorders market. Autoimmune diseases occur when the immune system erroneously attacks the body's healthy cells and tissues, perceiving them as foreign invaders. This misdirected immune response leads to inflammation and damage across various organs and systems. The rise in autoimmune diseases is attributed to a complex mix of environmental factors, genetic predispositions, and lifestyle changes. These diseases can cause primary immunodeficiency disorders by disrupting immune regulation and attacking immune cells, resulting in weakened or impaired immune responses. For example, in November 2024, data from Versorgungsatlas.de, an interactive online platform in Germany, revealed that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. This increasing prevalence of autoimmune diseases is a key driver behind the expansion of the primary immunodeficiency disorders market.
Leading companies in the primary immunodeficiency disorders market are focusing on the development of advanced therapies such as intravenous immunoglobulin (IVIG) therapy to enhance patient outcomes by improving immune function. IVIG therapy involves administering immunoglobulins (antibodies) derived from donor plasma directly into a patient's bloodstream through an IV. For instance, in June 2024, Grifols, a healthcare company based in Spain, received FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This new sugar-free, ready-to-use IgG solution, derived from human blood plasma, is intended for intravenous administration. It was approved in the U.S. for substitution therapy in patients with primary antibody deficiency syndromes. Yimmugo provides antibody replacement to support individuals with immune deficiencies, enhancing Grifols' portfolio of plasma-based treatments by offering a safer and more effective solution to protect against infections.
In April 2022, Grifols, S.A., a pharmaceutical company based in Spain, acquired Biotest AG for an undisclosed amount. This acquisition is aimed at accelerating growth and fostering innovation by expanding Grifols' plasma-derived medicines portfolio and strengthening its global market presence. Biotest AG, a biotechnology company based in Germany, specializes in plasma proteins and biological drugs.
Major players in the primary immunodeficiency disorders market are Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., and Chengdu Rongsheng Pharmaceutical Co Ltd.
North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary immunodeficiency disorders report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary immunodeficiency disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary immunodeficiency disorders market consists of revenues earned by entities by providing services such as immunoglobulin therapy, rehabilitation and support programs, educational and advocacy services, and personalized treatment plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary immunodeficiency disorders market also includes sales of vaccines, antibiotics, antifungals, and small molecule drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Immunodeficiency Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary immunodeficiency disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary immunodeficiency disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary immunodeficiency disorders market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Disease: Antibody Deficiency; Cellular Immunodeficiency; Innate Immune Disorders; Other Diseases
- 2) By Treatment: Immunoglobulin Replacement Therapy; Antibiotic Therapy; Stem Cell And Bone Marrow Transplantation; Gene Therapy; Other Treatments
- 3) By Diagnostic Type: Genetic Testing; Blood Testing; Flow Cytometry; Other Diagnostic Types
- 4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Research Institutions
- Subsegments:
- 1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID); IgA Deficiency; IgG Subclass Deficiency; Specific Antibody Deficiency
- 2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID); T-Cell Deficiency; DiGeorge Syndrome; Wiskott-Aldrich Syndrome
- 3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD); Complement Deficiencies; Toll-like Receptor Deficiencies; Chediak-Higashi Syndrome
- 4) By Other Diseases: Hyper IgM Syndrome; Hyper IgE Syndrome; Ataxia-Telangiectasia; Combined Immunodeficiencies With Syndromic Features
- Companies Mentioned: Pfizer Inc.; Thermo Fisher Scientific Inc.; Takeda Pharmaceuticals; CSL Behring; Baxter International Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Primary Immunodeficiency Disorders Market Characteristics
3. Primary Immunodeficiency Disorders Market Trends And Strategies
4. Primary Immunodeficiency Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Primary Immunodeficiency Disorders Growth Analysis And Strategic Analysis Framework
- 5.1. Global Primary Immunodeficiency Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Primary Immunodeficiency Disorders Market Growth Rate Analysis
- 5.4. Global Primary Immunodeficiency Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Primary Immunodeficiency Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Primary Immunodeficiency Disorders Total Addressable Market (TAM)
6. Primary Immunodeficiency Disorders Market Segmentation
- 6.1. Global Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Other Diseases
- 6.2. Global Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunoglobulin Replacement Therapy
- Antibiotic Therapy
- Stem Cell And Bone Marrow Transplantation
- Gene Therapy
- Other Treatments
- 6.3. Global Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Genetic Testing
- Blood Testing
- Flow Cytometry
- Other Diagnostic Types
- 6.4. Global Primary Immunodeficiency Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare Settings
- Research Institutions
- 6.5. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Antibody Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Common Variable Immune Deficiency (CVID)
- IgA Deficiency
- IgG Subclass Deficiency
- Specific Antibody Deficiency
- 6.6. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Cellular Immunodeficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Severe Combined Immunodeficiency (SCID)
- T-Cell Deficiency
- DiGeorge Syndrome
- Wiskott-Aldrich Syndrome
- 6.7. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Innate Immune Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chronic Granulomatous Disease (CGD)
- Complement Deficiencies
- Toll-like Receptor Deficiencies
- Chediak-Higashi Syndrome
- 6.8. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hyper IgM Syndrome
- Hyper IgE Syndrome
- Ataxia-Telangiectasia
- Combined Immunodeficiencies With Syndromic Features
7. Primary Immunodeficiency Disorders Market Regional And Country Analysis
- 7.1. Global Primary Immunodeficiency Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Primary Immunodeficiency Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Primary Immunodeficiency Disorders Market
- 8.1. Asia-Pacific Primary Immunodeficiency Disorders Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Primary Immunodeficiency Disorders Market
- 9.1. China Primary Immunodeficiency Disorders Market Overview
- 9.2. China Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Primary Immunodeficiency Disorders Market
- 10.1. India Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Primary Immunodeficiency Disorders Market
- 11.1. Japan Primary Immunodeficiency Disorders Market Overview
- 11.2. Japan Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Primary Immunodeficiency Disorders Market
- 12.1. Australia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Primary Immunodeficiency Disorders Market
- 13.1. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Primary Immunodeficiency Disorders Market
- 14.1. South Korea Primary Immunodeficiency Disorders Market Overview
- 14.2. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Primary Immunodeficiency Disorders Market
- 15.1. Western Europe Primary Immunodeficiency Disorders Market Overview
- 15.2. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Primary Immunodeficiency Disorders Market
- 16.1. UK Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Primary Immunodeficiency Disorders Market
- 17.1. Germany Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Primary Immunodeficiency Disorders Market
- 18.1. France Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Primary Immunodeficiency Disorders Market
- 19.1. Italy Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Primary Immunodeficiency Disorders Market
- 20.1. Spain Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Primary Immunodeficiency Disorders Market
- 21.1. Eastern Europe Primary Immunodeficiency Disorders Market Overview
- 21.2. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Primary Immunodeficiency Disorders Market
- 22.1. Russia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Primary Immunodeficiency Disorders Market
- 23.1. North America Primary Immunodeficiency Disorders Market Overview
- 23.2. North America Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Primary Immunodeficiency Disorders Market
- 24.1. USA Primary Immunodeficiency Disorders Market Overview
- 24.2. USA Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Primary Immunodeficiency Disorders Market
- 25.1. Canada Primary Immunodeficiency Disorders Market Overview
- 25.2. Canada Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Primary Immunodeficiency Disorders Market
- 26.1. South America Primary Immunodeficiency Disorders Market Overview
- 26.2. South America Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Primary Immunodeficiency Disorders Market
- 27.1. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Primary Immunodeficiency Disorders Market
- 28.1. Middle East Primary Immunodeficiency Disorders Market Overview
- 28.2. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Primary Immunodeficiency Disorders Market
- 29.1. Africa Primary Immunodeficiency Disorders Market Overview
- 29.2. Africa Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Primary Immunodeficiency Disorders Market Competitive Landscape And Company Profiles
- 30.1. Primary Immunodeficiency Disorders Market Competitive Landscape
- 30.2. Primary Immunodeficiency Disorders Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Takeda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. CSL Behring Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Primary Immunodeficiency Disorders Market Other Major And Innovative Companies
- 31.1. Grifols SA
- 31.2. Octapharma
- 31.3. Kedrion Biopharma
- 31.4. Miltenyi Biotec
- 31.5. LFB Group
- 31.6. Clinigen Limited
- 31.7. ADMA Biologics Inc.
- 31.8. Bio Products Laboratory Ltd
- 31.9. BD Biosciences
- 31.10. Cellectis SA
- 31.11. Florencia Healthcare
- 31.12. X4 Pharmaceuticals Inc.
- 31.13. Amber Lifesciences
- 31.14. bluebird bio Inc.
- 31.15. Chengdu Rongsheng Pharmaceutical Co Ltd
32. Global Primary Immunodeficiency Disorders Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Primary Immunodeficiency Disorders Market
34. Recent Developments In The Primary Immunodeficiency Disorders Market
35. Primary Immunodeficiency Disorders Market High Potential Countries, Segments and Strategies
- 35.1 Primary Immunodeficiency Disorders Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Primary Immunodeficiency Disorders Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Primary Immunodeficiency Disorders Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34935_Primary_Immunodeficiency_Disorders_GMR_2025
